Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
Business Wire•05/08/2026•07:05 ET
0
Whiz Insights
Get started
Create a free account to read the full story.